A safety committee will review all evidence from trials and studies to shed more light on the potential risk of NAION.

Glucagon-like peptide-1 receptor agonist use corresponded with risk reductions for dozens of diseases and adverse health ...

Learn more about a new study claiming that GLP-1s could be used to treat cognitive conditions like dementia, but may pose a ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

The study revealed that weight-loss drugs significantly benefit neurological and behavioral health, including decreased risks ...

Unless you have Wilson's disease, or you know someone who does, you've probably never heard of this rare genetic condition.

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduc ...

Weight loss drugs like Ozempic and Wegovy have been tied in a large, national study to a drop in the risk of developing dozens of health conditions. But the semaglutide-like drugs also appear to ...

Research has found that GLP-1 receptors, found in medications like Wegovy and Monjaro, may offer health benefits beyond the ...

"There was an increased risk of gastrointestinal disorders, hypotension, syncope (low blood pressure), arthritic disorders, ...

The use of weight-loss jabs may be associated with wider health benefits including lower risk of stroke and dementia, a study ...

Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed.The ...